NASDAQ:LXEO Lexeo Therapeutics (LXEO) Stock Price, News & Analysis $3.38 -0.04 (-1.17%) Closing price 04:00 PM EasternExtended Trading$3.29 -0.09 (-2.75%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Lexeo Therapeutics Stock (NASDAQ:LXEO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lexeo Therapeutics alerts:Sign Up Key Stats Today's Range$3.28▼$3.5950-Day Range$3.14▼$5.3752-Week Range$2.98▼$10.99Volume3.05 million shsAverage Volume997,343 shsMarket Capitalization$277.32 millionP/E RatioN/ADividend YieldN/APrice Target$18.13Consensus RatingBuy Company Overview Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for genetic and acquired diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material intended to address underlying disease mechanisms, with programs spanning central nervous system and cardiovascular conditions. Lexeo’s development portfolio includes investigational therapies for APOE4-associated Alzheimer’s disease, Friedreich’s ataxia, and inherited cardiac disorders such as LMNA-related dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. Its candidates are in clinical development, and the company’s research and development activities are primarily focused on advancing these therapies through clinical testing and regulatory evaluation. Founded in 2017 and headquartered in New York, Lexeo serves patients through a development program centered largely on the United States. The company is led by Chief Executive Officer R. Nolan Townsend and became a publicly traded company on the Nasdaq under the ticker symbol LXEO in 2023.AI Generated. May Contain Errors. Read More Lexeo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreLXEO MarketRank™: Lexeo Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 639th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingLexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLexeo Therapeutics has a consensus price target of $18.13, representing about 447.3% upside from its current price of $3.31.Amount of Analyst CoverageLexeo Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Lexeo Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lexeo Therapeutics are expected to decrease in the coming year, from ($1.18) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexeo Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexeo Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexeo Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lexeo Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.66% of the float of Lexeo Therapeutics has been sold short.Short Interest Ratio / Days to CoverLexeo Therapeutics has a short interest ratio ("days to cover") of 33.44, which indicates bearish sentiment.Change versus previous monthShort interest in Lexeo Therapeutics has recently increased by 0.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexeo Therapeutics does not currently pay a dividend.Dividend GrowthLexeo Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.31 News SentimentLexeo Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Lexeo Therapeutics this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $299,817.00 in company stock.Percentage Held by Insiders2.00% of the stock of Lexeo Therapeutics is held by insiders.Percentage Held by Institutions60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexeo Therapeutics' insider trading history. Receive LXEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXEO Stock News HeadlinesLexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Has Consensus Target Price of $18.12September 29 at 4:29 AM | americanbankingnews.comLeerink Partners Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)September 26, 2026 | theglobeandmail.comWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has noticed it. Altucher believes the filing could matter to as many as 1,806,000 Americans in the years ahead. He explains why Musk buried it and what it could mean, free of charge.September 30 at 1:00 AM | Paradigm Press (Ad)Lexeo Therapeutics (NASDAQ:LXEO) Earns Outperform Rating from Leerink PartnersSeptember 25, 2026 | americanbankingnews.comApertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich AtaxiaSeptember 23, 2026 | prnewswire.comLexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic ForumSeptember 23, 2026 | globenewswire.comLexeo Therapeutics, Inc. agreed to acquire Mantle Therapeutics Inc. for $21.3 million .September 22, 2026 | marketscreener.comMLexeo Therapeutics to Acquire Mantle Therapeutics for Up to $21.3 Million; Enters Three Research CollaborationsSeptember 22, 2026 | finance.yahoo.comSee More Headlines LXEO Stock Analysis - Frequently Asked Questions How have LXEO shares performed this year? Lexeo Therapeutics' stock was trading at $9.93 on January 1st, 2026. Since then, LXEO shares have decreased by 66.6% and is now trading at $3.3120. How were Lexeo Therapeutics' earnings last quarter? Lexeo Therapeutics, Inc. (NASDAQ:LXEO) posted its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.01. When did Lexeo Therapeutics IPO? Lexeo Therapeutics (LXEO) raised $127 million in an IPO on Friday, November 3rd 2023. The company issued 9,090,910 shares at a price of $13.00-$15.00 per share. How do I buy shares of Lexeo Therapeutics? Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexeo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexeo Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/12/2026Today9/30/2026Stifel 2026 Virtual Cardiometabolic Forum9/30/2026Next Earnings (Estimated)12/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 LXEO's financial health is in the Yellow zone, according to TradeSmith. LXEO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LXEO Previous SymbolNASDAQ:LXEO CIK1907108 Webwww.lexeotx.com Phone212-547-9879FaxN/AEmployees59Year Founded2018Price Target and Rating Average Price Target for Lexeo Therapeutics$18.13 High Price Target$30.00 Low Price Target$9.00 Potential Upside/Downside+436.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$99.96 million Net MarginsN/A Pretax MarginN/A Return on Equity-41.85% Return on Assets-38.03% Debt Debt-to-Equity RatioN/A Current Ratio13.89 Quick Ratio13.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book1.00Miscellaneous Outstanding Shares82,046,000Free Float80,405,000Market Cap$277.32 million OptionableNot Optionable Beta1.50 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:LXEO) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersLegendary U.S. Congressman Issues WarningDr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
